JP6967308B1 - 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤 - Google Patents

胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤 Download PDF

Info

Publication number
JP6967308B1
JP6967308B1 JP2020149878A JP2020149878A JP6967308B1 JP 6967308 B1 JP6967308 B1 JP 6967308B1 JP 2020149878 A JP2020149878 A JP 2020149878A JP 2020149878 A JP2020149878 A JP 2020149878A JP 6967308 B1 JP6967308 B1 JP 6967308B1
Authority
JP
Japan
Prior art keywords
derived
cells
therapeutic agent
cranial
culture supernatant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020149878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022016722A (ja
Inventor
▲祐▼輔 相良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kochi University NUC
Original Assignee
Kochi University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kochi University NUC filed Critical Kochi University NUC
Priority to PCT/JP2021/024837 priority Critical patent/WO2022004816A1/ja
Priority to CN202180047221.2A priority patent/CN115811981A/zh
Priority to US18/003,425 priority patent/US20230242870A1/en
Priority to JP2022534097A priority patent/JPWO2022004816A1/ja
Priority to EP21832276.6A priority patent/EP4173629A4/en
Application granted granted Critical
Publication of JP6967308B1 publication Critical patent/JP6967308B1/ja
Publication of JP2022016722A publication Critical patent/JP2022016722A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2020149878A 2020-06-30 2020-09-07 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤 Active JP6967308B1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/JP2021/024837 WO2022004816A1 (ja) 2020-06-30 2021-06-30 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
CN202180047221.2A CN115811981A (zh) 2020-06-30 2021-06-30 包含胎儿附属物来源组织细胞培养上清的脑神经损伤治疗剂
US18/003,425 US20230242870A1 (en) 2020-06-30 2021-06-30 Cranial nerve disorder therapeutic agent including culture supernatant of tissue cells derived from fetal appendage
JP2022534097A JPWO2022004816A1 (https=) 2020-06-30 2021-06-30
EP21832276.6A EP4173629A4 (en) 2020-06-30 2021-06-30 THERAPEUTIC AGENT FOR CRANIAL NERVE DISEASE USING CULTURE SUPERNATANT OF TISSUE CELLS FROM THE FETAL APPENDIX

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020113456 2020-06-30
JP2020113456 2020-06-30

Publications (2)

Publication Number Publication Date
JP6967308B1 true JP6967308B1 (ja) 2021-11-17
JP2022016722A JP2022016722A (ja) 2022-01-24

Family

ID=78509585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020149878A Active JP6967308B1 (ja) 2020-06-30 2020-09-07 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
JP2022534097A Pending JPWO2022004816A1 (https=) 2020-06-30 2021-06-30

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022534097A Pending JPWO2022004816A1 (https=) 2020-06-30 2021-06-30

Country Status (5)

Country Link
US (1) US20230242870A1 (https=)
EP (1) EP4173629A4 (https=)
JP (2) JP6967308B1 (https=)
CN (1) CN115811981A (https=)
WO (1) WO2022004816A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022004816A1 (https=) * 2020-06-30 2022-01-06
CN117679649A (zh) * 2022-09-09 2024-03-12 北京达尔文细胞生物科技有限公司 射频装置在治疗面瘫连带运动中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025100424A1 (ja) * 2023-11-10 2025-05-15 国立大学法人 東京大学 急性脳症治療剤及び急性脳症の治療方法
WO2025182103A1 (ja) * 2024-02-28 2025-09-04 セルソース株式会社 脳梗塞の機能予後改善用組成物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190556A (en) 1991-03-19 1993-03-02 O.B. Tech, Inc. Cord cutter sampler
US5372581A (en) 1993-07-21 1994-12-13 Minneapolis Children's Services Corporation Method and apparatus for placental blood collection
WO2002098361A2 (en) * 2001-06-01 2002-12-12 Xcyte Therapies, Inc. T cell induced tissue repair and regeneration
WO2005001080A2 (en) * 2003-06-27 2005-01-06 Ethicon, Incorporated Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2006071778A2 (en) * 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
EP2139497B1 (en) * 2007-04-13 2013-11-06 Stemnion, INC. Methods for treating nervous system injury and disease
JP6095893B2 (ja) * 2008-12-19 2017-03-15 デピュイ・シンセス・プロダクツ・インコーポレイテッド 傷害後の神経組織の再生および修復
SG174551A1 (en) * 2009-03-26 2011-10-28 Ethicon Inc Human umbilical cord tissue cells as therapy for alzheimer' s disease
MX2013006592A (es) * 2010-12-17 2014-02-06 Anthrogenesis Corp Tratamiento de lesion de la medula espinal y lesion traumatica de cerebro empleando celulas adherentes obtenidas del amnios.
US20120276215A1 (en) * 2011-04-26 2012-11-01 Riordan Neil H Therapeutic Conditioned Media
CN104321426A (zh) * 2012-03-28 2015-01-28 石匠株式会社 永生化干细胞以及以其生成物为有效成分的药物组合物和药物制剂
US10167448B2 (en) * 2013-12-12 2019-01-01 Samsung Life Public Welfare Foundation Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
DK3145493T3 (da) * 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
EP3307286B1 (en) * 2015-06-12 2023-01-11 Hudson Institute of Medical Research Allogeneic mammalian amniotic exosomes for treating a fibrotic disease
WO2017204231A1 (ja) * 2016-05-24 2017-11-30 国立大学法人 東京大学 臍帯由来細胞を含む脳障害の治療剤
KR20190109389A (ko) * 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
CA3064064A1 (en) * 2017-05-16 2018-11-22 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
CA3069805A1 (en) * 2017-07-14 2019-01-17 Orbsen Therapeutics Limited Cd39 stromal stem cells methods of isolation and use
JP2020093988A (ja) * 2018-12-11 2020-06-18 株式会社 バイオミメティクスシンパシーズ 腸溶性カプセル
JP6967308B1 (ja) * 2020-06-30 2021-11-17 国立大学法人高知大学 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022004816A1 (https=) * 2020-06-30 2022-01-06
CN117679649A (zh) * 2022-09-09 2024-03-12 北京达尔文细胞生物科技有限公司 射频装置在治疗面瘫连带运动中的应用

Also Published As

Publication number Publication date
JP2022016722A (ja) 2022-01-24
US20230242870A1 (en) 2023-08-03
EP4173629A4 (en) 2024-08-21
CN115811981A (zh) 2023-03-17
EP4173629A1 (en) 2023-05-03
JPWO2022004816A1 (https=) 2022-01-06
WO2022004816A1 (ja) 2022-01-06

Similar Documents

Publication Publication Date Title
JP6967308B1 (ja) 胎児付属物由来組織細胞培養上清を含む脳神経障害治療剤
Baez-Jurado et al. Secretome of mesenchymal stem cells and its potential protective effects on brain pathologies
Cunningham et al. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke
US20200306318A1 (en) Adherent cells from placenta and use of same in disease treatment
US9084787B2 (en) Methods of treating spinal cord injury and minimizing scarring
US8263400B2 (en) Method for expanding adult stem cells from blood and compositions and methods for using the same
US9688733B2 (en) Method for treating spinal cord injury using HMGB1 fragment
Ejma et al. The role of stem cells in the therapy of stroke
KR102128224B1 (ko) 향상된 산후 부착형 세포 및 그의 제조 방법
JP2023105066A (ja) 組織治癒剤
CN120574767A (zh) 人胎盘源促血管干细胞hPASCs及其应用
Pati et al. Neurogenic plasticity of mesenchymal stem cell, an alluring cellular replacement for traumatic brain injury
CN112118851A (zh) 使用神经干细胞诱导血管生成的方法
WO2022004823A1 (ja) 臍帯血単核球細胞の培養上清を含む脳神経障害治療剤
CA3101965A1 (en) Tissue healing agent
Ma et al. SA/Col/SDF-1 neural scaffold promotes the homing of BMSCs and functional recovery in a rat model of traumatic brain injury
Siddiqui et al. Mechanisms Underpinning Beneficial
EP2035093A1 (en) Methods of treating spinal cord injury and minimizing scarring
WO2018051340A1 (en) A process for retrieval of matrix dependent mesenchymal stromal cells from tissue
WO2022004822A1 (ja) 胎児付属物由来組織細胞及び／又は臍帯血細胞を培養するための海洋深層水を含む培地
Cohen Unresolved inflammation following spinal cord injury-causes and effects on the central nervous system
HK1212888B (en) Novel method for treating spinal cord injury using hmgb1 fragment
HK1174356B (en) Adherent cells from placenta and use of same in disease treatment

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200915

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200915

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20200929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200925

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20201029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211018

R150 Certificate of patent or registration of utility model

Ref document number: 6967308

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R154 Certificate of patent or utility model (reissue)

Free format text: JAPANESE INTERMEDIATE CODE: R154

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250